Introduction
============

The number of patients undergoing rotator cuff repair \[arthroscopic rotator cuff repair (ARCR)\] by arthroscopy as a day procedure is increasing annually.^[@R1]^ The procedure is associated with significant postoperative pain and effective analgesia is required for successful day-case surgery.^[@R2],[@R3]^ Although ISB,^[@R4]^ and more particularly continuous interscalene catheter block, is considered to be the most effective analgesic technique for ARCR,^[@R5]^ it is frequently associated with phrenic nerve block,^[@R6],[@R7]^ even with the use of ultrasound and low volumes of local anaesthetic.^[@R8]^ The difficulties in implementing and monitoring a perineural catheter at home have led to many anaesthesiologists to choose a single injection technique so that patients can be discharged on the same day as surgery with a satisfactory level of pain control.^[@R9]^

Phrenic nerve block is a concern to many anaesthesiologists and surgeons, as it may lead to respiratory complications after hospital discharge, preventing discharge from hospital on the same day.^[@R10]^ There are little data on the postoperative clinical consequences in the home, but it is known that changes in spirometry variables have been associated with ISB,^[@R11]^ whatever the site of injection around the roots, anterior or posterior. Nevertheless, effective regional anaesthesia that persists for as long as possible and that is compatible with local organisational constraints, is essential for this procedure because multimodal analgesia alone is insufficient.^[@R12]^

Several alternatives to ISB exist that are associated with a lower incidence of phrenic nerve paresis.^[@R8]^ Supraclavicular block (SCB) decreases the risk of phrenic nerve involvement, particularly when guided by ultrasound,^[@R13]^ but nevertheless the associated level of phrenic nerve paresis is not negligible.^[@R14]^ This technique, which has been linked to a risk of pneumothorax when carried out by neurostimulation only,^[@R15]^ has now been revived and is included among the regional anaesthesia techniques considered to be well tolerated in terms of respiratory risk, especially when guided by ultrasound.^[@R16]--[@R18]^ Many studies have demonstrated a lower risk of phrenic paresis with ultrasound-guided SCB,^[@R19],[@R20]^ even when using low volumes of local anesthesic.^[@R21]^ Published studies have demonstrated that SCB is an effective alternative to ISB,^[@R22]^ and many studies have shown that ultrasound-guided SCB is a safe technique for ambulatory shoulder surgery in terms of respiratory complications.^[@R23]--[@R25]^ SCB is therefore a real alternative to ISB for ambulatory ARCR,^[@R26]^ but comparative studies are necessary to evaluate the analgesic results more than 24 h after surgery, particularly in terms of oral morphine consumption at home, given the fact that in our centre, patients are discharged less than 12 h after hospital admission. Most studies published to date have only shown similar intra-operative opioid analgesic requirements between ISB and SCB,^[@R27]^ or equivalent postoperative analgesia in the first 24 h only,^[@R28]^ and all findings are based on a small number of patients.

We carried out a single-centre randomised study to determine whether SCB is noninferior to ISB in terms of postoperative analgesia following ambulatory ARCR. Analgesic efficacy was determined by oral morphine use and/or pain scores assessed using a numerical rating scale (NRS) after hospital discharge on the evening of surgery. Our hypothesis was that SCB would provide similar or better analgesia to ISB in patients returning home after surgery.

Materials and methods
=====================

Study design
------------

This randomised, single-blind, noninferiority study was carried out in the Hôpital Privé Jean Mermoz, Centre Paul Santy, Lyon, France, between September 2016 and October 2017.

The study was approved by the local ethics committee (CPP) South-East III (France) on 3 June 2016 prior to patient enrolment (CPP number 2016-023 B) and was carried out in accordance with the Declaration of Helsinki. The trial was registered prior to patient enrolment on [www.clinicaltrialsregister.eu](http://www.clinicaltrialsregister.eu/) (EU Clinical Trials Register): ID-RCB clinical trial registration EudraCT number 2016-A00747-47; principal investigator: Julien Cabaton; date of registration: 3 June 2016.

All participants in the trial gave their written informed consent before taking part.

Patients
--------

Adults undergoing ARCR performed by a single surgeon (NJ), under regional anaesthesia and general anaesthesia, and returning home on the evening of their surgery (hospital stay \<12 h) were recruited. Exclusion criteria included the inability to return home on the evening of surgery (for a medical or other reason); administration of oral morphine derivatives before their surgery; contraindications for regional anaesthesia or regional anaesthesia not performed; contraindication to oral morphine derivatives; refusal to participate in the study or failure to record consent; and development of a complication during implementation of regional anaesthesia. Patients who were due to undergo ambulatory ARCR were asked to participate in the study during their surgical consultation or during their meeting with the anaesthesiologist. All were provided with specific information on the study and a consent form to sign after being given time to reflect on the procedures.

On the day of admission to the clinic, patients were randomly allocated to one of two parallel groups. Patients in both SCB and ISB groups received a single injection block. Randomisation was 1: 1 using the SAS 9.4 software (SAS Institute Inc., Cary, North Carolina, USA), and no stratification variable was taken into account. Two anaesthesiologists only took part in the study and performed the allocated block (no blinding at this stage), but neither the patient, nor the surgeon, nor the clinical research associate carrying out the follow-up telephone call knew which regional anaesthesia technique had been used.

Pre-operative management
------------------------

In the anaesthesia consultation, the process was explained; all would receive a standard general anaesthesia preceded by ISB or SCB according to group allocation. Successful management would allow return home on the same evening as their procedure (ambulatory criteria).

During this consultation, the patients received written information, consent forms for participation in the study and also a standardised prescription for oral multimodal analgesia^[@R29]^ to be taken systematically after returning home. These prescriptions included codeine-paracetamol 1 g x four times per day, ketoprofen 100 mg x two times per day and nefopam 20 mg x four times per day. Fast-acting oral morphine sulphate, 10 mg x four times per day if necessary, was prescribed on a different prescription, to be taken only if pain relief proved inadequate. The dose was based on the maximum dose required to treat severe pain.

Peri-operative management
-------------------------

SCB and ISB were both performed on conscious sedated patients before general anaesthesia in a standardised manner by one of the two anaesthesiologists in our team: after oral premedication with sublingual midazolam 0.1 mg kg^−1^ conscious monitoring was applied; sedation with 0.2 mg kg^−1^ intravenously (i.v.) ketamine was given before ultrasonography with a Imagic Agile - Esaote Medical (Genova, Italy) or Logiq V2 - General Electric (Boston, USA) ultrasound machine; ultrasound guidance was associated with nerve stimulation performed with a Stimuplex HNS 12 - B Braun (Bethlehem, USA) set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; a single perineural injection was performed with a 50 mm needle Vygon (Swindon, UK) containing a mixture of 100 mg levobupivacaine (20 ml, 0.5%) and clonidine (1 μg kg body weight^−1^) as is the common local protocol and in the absence of contraindications; the site of injection for ISB was the C6 plexus nerve root with a posterior in-plane approach, with neurostimulation control and ultrasound-controlled extra-plexus injection of the mixture posterior to the C6 root (Fig. [1](#F1){ref-type="fig"}a); and the site of injection for SCB was superficial and lateral to the trunks of the brachial plexus and not directly deep inside the 'corner pocket' zone, with neurostimulation control and visualisation of the lung (Fig. [1](#F1){ref-type="fig"}b).

![Sites of injection of anaesthesia for arthroscopic rotator cuff repair. (a) The site of injection for ultrasound-guided interscalene block was the C6 plexus nerve root with a posterior in-plane approach, with neurostimulation control, and ultrasound-controlled extraneural injection of the mixture. (b) The site of injection for supraclavicular block was superficial and lateral to the trunks of the brachial plexus, and not directly deep in the 'corner pocket' zone, with neurostimulation control and visualisation of the lung.](ejanet-36-778-g001){#F1}

General anaesthesia was performed after regional anaesthesia according to the same protocol for all patients, with endotracheal intubation following i.v. propofol, sufentanil and cis-atracurium. All patients were placed in the beach-chair position. Prophylactic postoperative nausea and vomiting prevention with i.v. 1.25 mg droperidol was given. Dexamethasone 8 mg i.v. was given to potentiate the duration of regional anaesthesia, and in the absence of contraindications, multimodal i.v. analgesia was given from induction with paracetamol 1 g, ketoprofen 100 mg and nefopam 20 mg. General anaesthesia was maintained with inhaled desflurane, end-tidal minimal alveolar concentration 0.8 to 1.0 MAC and additional injections of sufentanil if required.

Surgery was carried out on all patients by a single surgeon using the same arthroscopic technique (one, two or three tendons could be repaired) and the same beach-chair installation. No open repair was performed and an acromioplasty was performed at the end of the procedure.

Patients were excluded from the study if they underwent any nonarthroscopic repair (peri-operative conversion to open technique), or any other type of regional anaesthesia.

Outcomes and data collection
----------------------------

Data were collected by the anaesthesiologist responsible and by nurses involved in patient care during hospital admission, and by a clinical research assistant who telephoned patients at home on postoperative Day 1 and Day 2. Nurses and the research assistant were blinded to the type of anaesthesia.

The primary outcome was oral morphine consumption in mg at home during the 2 days postsurgery. The secondary outcomes were pain scores using a NRS (0 = no pain, 10 = worst imaginable pain); in the recovery room 1 h after surgery and in the day-surgery unit 8 h after surgery, and on Day 1 and Day 2 by phone call; the duration of motor blockade; the time in hours from regional anaesthesia to the time at which forearm and/or arm movement became possible; the duration of sensory blockade; the time in hours from regional anaesthesia to the time that sensation (pulling of the scar tissue, itching/tingling, pain) returned; side effects linked to morphine such as nausea, vomiting, constipation, generalised pruritus, excessive sedation visual hallucinations, spatio-temporal disorientation or confusion, coma, respiratory arrest with a need to call the emergency services; complications at home requiring a consultation with a doctor or persistent perineural block; and overall satisfaction with treatment on Day 2. Items (ii) to (vi) were ascertained by telephone questionnaire on Day 1 and Day 2. The data were then stored on a dedicated website created for the study.

Statistical analysis
--------------------

Forty-eight patients were required per group to have an 80% power of demonstrating noninferiority of SCB compared with ISB (one-sided 2.5% level), with an anticipated loss to follow-up of 10%. This calculation was based on the hypothesis of an expected difference in mean morphine consumption between the two techniques (SCB vs. ISB) of 10 mg and on a difference in standard deviation (SD) of morphine consumption of 35 mg in the first 48 h postsurgery. This was based on the results of a retrospective study carried out in our centre in 2014 to 2015 on 323 ARCR patients and their mean oral morphine use.^[@R30]^ The primary analysis was based on the per-protocol cohort (all patients without any deviations from the protocol and who received the correct treatment allocated by randomisation). A robustness analysis was performed on the intent-to-treat (ITT) principle and involved all patients who were randomly assigned to the two groups, including observed data for all patients who started the assigned treatment, regardless of whether it was continued or not. The difference between mean morphine consumption in the SCB group and mean morphine consumption in the ISB group was calculated with 95% CIs. If the upper limit of the 95% CI was less than 30 mg, noninferiority of SCB compared with ISB would be demonstrated.

Intergroup differences were assessed using the Wilcoxon or Student\'s *t*-test for continuous variables and χ^2^ or Fisher\'s exact test for categorical variables. All statistical analyses were carried out using SAS version 9.4 (SAS Institute Inc.).

Results
=======

One-hundred and ten patients were included in the study. One-hundred and seven patients were randomised and analysed in the ITT analysis: 54 in the SCB group and 53 in the ISB group. One patient was randomised to the SCB group but received ISB; the safety analysis therefore included 53 and 54 patients in the SCB and ISB groups, respectively. One patient did not receive the treatment allocated by randomisation, two patients did not receive the telephone call on Days 1 and 2, and one patient could not return home the same evening as surgery; hence, 103 patients were analysed in the per-protocol analysis (as shown in Fig. [2](#F2){ref-type="fig"}).

![Consort Diagram.](ejanet-36-778-g002){#F2}

The baseline characteristics of the study patients are summarised in Table [1](#T1){ref-type="table"}. Overall, 57% of patients were men, median age was 58 years and 16% of patients had a BMI of more than 30 kg m^−2^. All except 10 had a history of shoulder surgery and the majority (77%) had difficulties with their left shoulder. Fifty-five percent of patients had one ruptured tendon and half had undergone the usual treatments before surgery. The baseline characteristics were similar in the two groups in the per-protocol and ITT analyses (Table [1](#T1){ref-type="table"}).

###### 

Baseline characteristics

                               PP                ITT                                                                     
  ---------------------------- ----------------- ----------------- ----------------- ----------------- ----------------- -----------------
  Male                         32 (62)           27 (53)           59 (57)           33 (61)           28 (53)           61 (57)
  Age (years)                  57 \[51 to 65\]   58 \[54 to 65\]   58 \[52 to 65\]   57 \[50 to 65\]   58 \[54 to 65\]   58 \[52 to 65\]
  BMI class                                                                                                              
   \<18.5                                        2 (4)             2 (2)                               2 (4)             2 (2)
   18.5--25                    20 (39)           16 (31)           36 (35)           20 (37)           17 (32)           37 (35)
   25--30                      23 (44)           25 (49)           48 (47)           23 (43)           26 (49)           49 (46)
   ≥30                         9 (17)            8 (16)            17 (16)           11 (20)           8 (15)            19 (18)
  History of surgery           49 (94)           44 (86)           93 (90)           51 (94)           46 (87)           97 (91)
  Shoulder                                                                                                               
   Right                       42 (81)           37 (73)           79 (77)           43 (80)           38 (72)           81 (76)
   Left                        10 (19)           14 (27)           24 (23)           11 (20)           15 (28)           26 (24)
  Number of tendons ruptured                                                                                             
   1                           26 (50)           31 (61)           57 (55)           27 (50)           31 (59)           58 (54)
   2                           19 (36)           19 (37)           38 (37)           20 (37)           21 (40)           41 (38)
   3                           7 (14)            1 (2)             8 (8)             7 (13)            1 (2)             8 (8)
  Usual treatment              23 (44)           29 (57)           52 (51)           24 (44)           30 (57)           54 (51)

All values shown are *n* (%) or median \[IQR\].

IQR, interquartile range; ISB, interscalene block; ITT, intent to treat; PP, per protocol; SCB, supraclavicular block.

Four patients discontinued the study prematurely, two in the SCB group and two in the ISB group.

Primary endpoint
----------------

In the per-protocol analysis, mean morphine consumption in the 48 h following surgery was 9.4 mg (95% CI: 5.4 to 13.5) and 14.7 mg (95% CI: 9.6 to 19.8) in the SCB and ISB groups (*P* \< 0.001), respectively, yielding a difference of −5.3 (95% two-sided CI: −11.7 to 1.17). The upper limit of the 95% CI (1.17) was less than 30 mg, demonstrating noninferiority of SCB compared with ISB. As noninferiority had been demonstrated, we tested the superiority of SCB compared with ISB, but this was not significant.

In the ITT analysis, mean morphine consumption in the 48 h following surgery was 9.4 vs. 14.7 mg in the SCB and ISB groups, respectively, yielding a difference of −5.3 (upper limit of 95% one-sided CI: 1.17). The results for the ITT analysis were identical to those for per-protocol because the four patients excluded from the ITT analysis had no data collected concerning their morphine consumption.

Secondary endpoints
-------------------

The results for morphine consumption on Day 1 and Day 2, pain scores and duration of motor and sensory blockade are summarised in Table [2](#T2){ref-type="table"}. No statistically significant difference was observed between the groups for the pain scores in the recovery room (immediately after the end of the surgery) and in the ambulatory ward, just before discharge home (between 5 and 12 h after ISB or SCB was performed). In the per-protocol analysis, mean morphine consumption was 5.0 and 4.4 mg on Days 1 and 2, respectively, in the SCB group, and 9.2 mg and 5.5 mg, respectively, in the ISB group. In the SCB group, 40% of patients had intense pain (moderate or severe) on Day 1 and this decreased to 35% on Day 2. In the ISB group, 47% had intense pain on Day 1 and Day 2. No significant difference was observed between the two groups regarding the duration of motor or sensory blockade.

###### 

Morphine consumption and pain scores on days 1 (D1) and 2 (D2) and block duration

                                                                                        Per-protocol population                                           
  ------------------------------------------------------------------------------------- ------------------------- ------------------- ------------------- --------
  Morphine consumption at 24 h (mg)                                                     5.0 ± 9                   9.2 ± 13            7.1 ± 11            
  Morphine consumption at 24 h                                                                                                                            
   No                                                                                   38 (73)                   27 (53)             65 (63)             0.0342
   Yes                                                                                  14 (27)                   24 (47)             38 (37)             
  Morphine consumption at 48 h (mg)                                                     4.4 ± 7                   5.5 ± 8             5.0 ± 7             
  Morphine consumption at 48 h                                                                                                                            
   No                                                                                   36 (69)                   31 (61)             67 (65)             0.3687
   Yes                                                                                  16 (31)                   20 (39)             36 (35)             
  Pain score in recovery room                                                           0.5 ± 1                   0.5 ± 2             0.5 ± 2             0.5906
  Pain score before leaving the hospital                                                0.2 ± 1                   0.5 ± 1             0.4 ± 1             
  Pain score at 24 h                                                                    3.3 ± 3                   3.4 ± 3             3.3 ± 3             0.3574
  Pain score at 24 h                                                                                                                                      
   No pain or mild pain (\<4)                                                           31 (60)                   27 (53)             58 (56)             
   Intense pain (≥4)                                                                    21 (40)                   24 (47)             45 (44)             
  Pain score at 48 h                                                                    2.8 ± 2                   3.4 ± 3             3.1 ± 2             
  Pain score at 48 h                                                                                                                                      
   No pain or mild pain (\<4)                                                           34 (65)                   27 (53)             61 (59)             
   Intense pain (≥4)                                                                    18 (35)                   24 (47)             42 (41)             
  Duration of motor block (h)                                                           20.8 \[14 to 24\]         20.3 \[18 to 24\]   20.6 \[15 to 26\]   
  Duration of sensory block (h)Data are given as mean ± SD, *n* (%) or median \[IQR\]   19.7 \[14 to 22\]         20.3 \[14 to 23\]   19.9 \[14 to 23\]   

ISB, interscalene block; SCB, supraclavicular block.

Safety
------

Adverse events are summarised in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. The most frequent adverse events in the whole cohort were somnolence (19%) and nausea (14%). Five events were considered to be possibly related to treatment: one patient had heartburn, one patient had hot flushes and vomiting, one had nausea and two patients had episodes of somnolence. No patient suffered a serious adverse event and only one in the ISB group had a severe adverse event (heartburn) possibly related to treatment. The treatments were well tolerated and few adverse events occurred during the study.

###### 

Adverse events

                                                               BMI \<30 kg m^−2^   BMI ≥30 kg m^−2^   Safety cohorts                                                 
  ------------------------------------------------------------ ------------------- ------------------ ---------------- -------- -------- -------- -------- --------- ---------
  Patient with at least one AE                                 5 (12)              10 (22)            15 (17)          2 (20)   2 (22)   4 (21)   7 (13)   12 (22)   19 (18)
  Patient with at least one mild AE                            4 (9)               7 (16)             11 (13)          1 (10)   1 (11)   2 (11)   5 (9)    8 (15)    13 (12)
  Patient with at least one moderate AE                        1 (2)               2 (4)              3 (3)            1 (10)   1 (11)   2 (11)   2 (4)    3 (6)     5 (5)
  Patient with at least one severe AE                                              1 (2)              1 (1)                                       --       1 (2)     1 (1)
  Patient with at least one ongoing AE                         2 (5)               2 (4)              4 (5)                                       2 (4)    2 (4)     4 (4)
  Patient with at least one AE possibly related to treatment                       4 (9)              4 (5)            1 (10)            1 (5)    1 (2)    4 (7)     5 (5)

Data are shown as *n* (%).

AE, adverse event; ISB, interscalene block; SCB, supraclavicular block.

###### 

Types of adverse events

  Patient   Safety arm   Adverse event                       Place         Start date          End date            Intensity
  --------- ------------ ----------------------------------- ------------- ------------------- ------------------- -----------
  1         SCB          Constipation and stomach pain       Home          17 May 2017                             Mild
  2         SCB          Dryness of the mouth and stress     Home          12 May 2017         12 May 2017         Mild
  3         ISB          Redness of thorax                   Home          04 May 2017         04 May 2017         Moderate
  4         ISB          Sensation of not standing upright   Home          04 July 2017        04 July 2017        Mild
  5         SCB          Hot flushes                         Home          16 May 2017         16 May 2017         Mild
  5         SCB          Constipation                        Home          16 May 2017         17 May 2017         Mile
  6         SCB          Somnolence                          Home          15 November 2016    16 November 2016    Mild
  7         ISB          Dizziness                           Home          30 November 2016                        Mild
  8         ISB          Heartburn                           Home          19 September 2017   19 September 2017   Severe
  9         ISB          Fall                                Other         24 November 2016    24 November 2016    Mild
  10        ISB          Somnolence                          Home          26 October 2016                         Mild
  11        ISB          Redness and shortage of breath      Home          11 May 2017         11 May 2017         Moderate
  12        SCB          Stomach pain                        Home          11 May 2017         11 May 2017         Moderate
  13        ISB          Nausea                              Home          30 March 2017       30 March 2017       Mild
  14        ISB          Somnolence                          Home          25 October 2016     26 November 2016    Mild
  15        ISB          Vomiting                            Home          04 September 2017   04 September 2017   Moderate
  15        ISB          Feeling hot and vomiting            Home          06 September 2017   06 September 2017   Moderate
  16        SCB          Stomach pain and diarrhoea          Home          16 May 2017         17 May 2017         Moderate
  17        SCB          Excessive somnolence                Home          28 October 2016                         Mild
  18        ISB          Nausea                              Outpatients   24 October 2016     24 October 2016     Mild
  19        ISB          Nausea                              Home          17 November 2016    17 November 2016    Mild

ISB, interscalene block; SCB, supraclavicular block.

Overall, 98% in the SCB group and 90% in the ISB group were satisfied with their treatment.

Discussion
----------

Our results demonstrate that SCB is noninferior to ISB in terms of oral morphine consumption given as part of multimodal analgesia, in the 48 h following ambulatory ARCR, in a large number of patients. In addition, no significant difference was found between ISB and SCB in terms of the duration of sensory and motor blockade (mean 20 h), with a similar duration to previous reports for ISB with the addition of i.v. dexamethasone.^[@R9]^ The absence of a significant difference in the duration of sensory blockade and in the pain scores in the first hours after surgery is in agreement with the results of our study, which showed no inferiority of SCB in terms of analgesia.

Similar studies published recently have shown comparable results to ours, but with a smaller number of patients^[@R14]^ and other types of surgery including arthroplasty,^[@R31]^ forearm surgery^[@R10]^ and open-sky nonarthroscopic surgery,^[@R32]^ but did not investigate oral morphine use after the return of the patients to their homes.^[@R33]^

Our study is a noninferiority study, but the difference in oral morphine consumption observed seems to indicate a difference in favour of SCB, especially as all of our patients received multimodal analgesia in addition to the morphine given as rescue analgesia. Although this difference was statistically significant, the design of the study did not allow use to conclude that SCB is superior to ISB, because the difference was observed only on day 1 postsurgery and concerned a binary nonquantitative criterion. Moreover, the morphine consumption found in our study was lower than expected from local data.^[@R29]^

Combining axillary nerve block with suprascapular nerve block^[@R34]^ might be a way to avoid phrenic nerve block. Studies comparing this combination have recently been published, but the results vary, often with inferior analgesic efficacy to ISB,^[@R35]^ or limited early postoperative efficacy.^[@R36]^

Our study did not investigate the impact of the two blocks on respiratory outcomes and in particular did not include ultrasound assessment of a possible phrenic palsy. This is a major limitation of the design of our study that could not be modified after we started to recruit patients. However, a recent meta-analysis demonstrated no great difference between ISB and SCB in the development of dyspnea.^[@R37]^ This limits the conclusions of our study for clinical practice, but confirms the equivalence in analgesic efficacy between ISB and SCB. It should be noted that no respiratory event occurred among the adverse events reported by any of the patients in the two groups in our study (Table [4](#T4){ref-type="table"}), and there was no important difference in adverse events between patients with a BMI less than 30 kg m^−2^ and those with a BMI at least 30 kg m^−2^. No patient had a contraindication to phrenic paresis, and this reassured us about the feasibility of safely managing these ambulatory patients, even the obese ones. However, the exclusion of patients who were hospitalised on the evening of their surgery is a methodological limitation of our study, because this could have been due to complications of adverse event. Similarly, despite the prescription of morphine, which is often feared for its side effects, only one patient among the 107 randomised presented with vomiting and vomiting. Nevertheless, almost 20% of our patients were somnolent, which could be explained by the systematic prescription of codeine.

Concerning possible confounding factors, it should be noted that our patients were all operated on by the same surgeon and that a subgroup analysis by number of tendons repaired did not demonstrate any significant difference.

However certain methodological choices in our study limit the conclusions for clinical practice. The timescale of our study may be different to other reported studies, as a patient is described as ambulatory in France if they are discharged from hospital within 12 h, whereas the time period in other countries is less than 23 h. We chose to use higher concentrations of levobupivacaine than in recent studies^[@R38]--[@R40]^ in order to obtain a longer block despite our concern that the phrenic nerve should be spared.^[@R41],[@R42]^ Perineural catheters are rarely inserted in our practice due to a high rate of accidental removals. Reducing the volume of local anaesthetic may not help because some studies have not shown any reduction in phrenic paresis by decreasing the volume injected from 20 to 10 ml.^[@R43]^

The difference in consumption of oral morphine considered to be clinically significant is debatable, as is the observation period of 48 h: a longer period would have been preferred and another model of statistical analysis chosen, although our model seems to be the best adapted.^[@R31]^ Finally, our results only show pain scores at 24 and at 48 h despite intensive multimodal analgesia, and we should remember that arthroscopic shoulder surgery can result in severe postoperative pain, even after the second day postsurgery. Analgesia via a perineural catheter would have been a more effective method, taking into account the fact that around 40% of our patients described intense pain after the wearing off of their block, but the use of morphine after removal of the catheter is necessary whatever the choice of technique used for regional anaesthesia.

Conclusion
==========

Despite the limitations of our study, especially the absence of evaluation of the phrenic nerve palsy, no important difference was found between SCB and ISB in terms of postoperative analgesia with oral morphine in the 48 h following ambulatory ARCR. Further studies are required to confirm these results, with an evaluation of the respiratory consequences of these techniques when used in ambulatory shoulder surgery. Taking into account the recent literature, a superiority study would now be the way to compare these two types of nerve block.
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